Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 Nov 15;119(22):3906-9.
doi: 10.1002/cncr.28301. Epub 2013 Sep 4.

Managing localized prostate cancer in the era of prostate-specific antigen screening

James D Brooks  1
Affiliations
Editorial

Managing localized prostate cancer in the era of prostate-specific antigen screening

James D Brooks. Cancer. .

Abstract

Because prostate cancer is diagnosed by blind biopsy, there is underlying uncertainty as to its extent and aggressiveness, evidenced by 40% of cases being upgraded after surgery compared to the diagnostic biopsy. This uncertainty contributes to the overtreatment of low risk localized prostate cancer that fuels the current debate surrounding prostate cancer screening and treatment. This issue presents presents a validated tool that uses clinical variables to predict upgrading of Gleason score 6 prostate cancer. Ideally, this and other tools should increase the acceptance, safety and use of active surveillance in men with localized prostate cancer detected by screening and help to address the problem of overtreatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The author declares no conflicts of interest

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013;63(1):11–30. - PubMed
    1. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. The New England journal of medicine. 2004;350(22):2239–46. - PubMed
    1. Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9. - PMC - PubMed
    1. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. The New England journal of medicine. 2012;366(11):981–90. - PMC - PubMed
    1. Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Medical care. 2013;51(4):295–300. - PMC - PubMed

Publication types